Evidence map›Paper›PMID 41969226›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Vorinostat Potentiates Chemoimmunotherapy in Immune-Enriched Pancreatic Cancer.

Chen Chen, Dingru Li, Yingna Liao, Zehua Wang, Chunbin Zhu, Zifeng Zhang, Liquan Jin, Yueyue Chen, Jiaoshun Chen, Junyi Xu and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Chen ChenDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Dingru LiDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Yingna LiaoDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Zehua WangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Chunbin ZhuDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Zifeng ZhangDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Liquan JinDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Yueyue ChenDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Jiaoshun ChenDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Junyi XuDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Miaoyan WeiDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Rong TangDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Xianjun YuDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID https://orcid.org/0000-0002-6697-7143
Si ShiDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.

Funding

National Natural Science Foundation of China 82203655National Natural Science Foundation of China 82473391National Natural Science Foundation of China U25C2038Noncommunicable Chronic Diseases-National Science and Technology Major Project 2024ZD0525500Noncommunicable Chronic Diseases-National Science and Technology Major Project 2024ZD0525501Noncommunicable Chronic Diseases-National Science and Technology Major Project 2024ZD0525505Science and Technology Commission of Shanghai Municipality 23ZR1479300Science and Technology Commission of Shanghai Municipality YDZX20243100002003Shanghai Municipal Health Industry Clinical Research Special Program 202440071Shuguang Program of Shanghai Municipal Education Commission and Shanghai Education Development Foundation 25SG10
6 · The paper itself

Abstract

Although pancreatic ductal adenocarcinoma (PDAC) is generally considered an immunologically "cold" tumor, approximately 20% of cases can be classified as immune-hot. However, this immune-enriched (IE) phenotype does not confer a significant survival advantage, highlighting the need to investigate its underlying mechanisms and identify effective therapies. By integrating in vitro drug screening and in silico sensitivity prediction, we identified the HDAC inhibitor vorinostat (SAHA) as a potent sensitizer to chemoimmunotherapy specifically in the IE-PDAC. This effect was validated using T cell-organoid co-cultures and patient-derived xenografts with humanized immune systems. Mechanistically, abundant cytokines (TNF-α, FGF) in the IE tumor microenvironment promote FASN and PARP9 expression. This leads to free fatty acid accumulation and enhanced oxidative phosphorylation, supporting tumor cell survival. SAHA disrupts this "metabolic trap" by concurrently suppressing FASN and PARP9. Single-cell RNA sequencing revealed that the Gemcitabine-SAHA combination remodels the tumor microenvironment by enhancing CD8

Indexed as

Carcinoma, Pancreatic DuctalImmunotherapyPancreatic NeoplasmsVorinostatAnimalsDeoxycytidineGemcitabineHistone Deacetylase InhibitorsHumansMiceTumor MicroenvironmentDeoxycytidineGemcitabineHistone Deacetylase InhibitorsVorinostatchemoimmunotherapyimmune‐enrichedmetabolic reprogramingPDACSAHA

Identifiers

PMID41969226
PMCPMC13292265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.